BridgeBio Pharma, Inc. believes it has a long-term blockbuster on its hands in acoramidis, a high-affinity stabilizer of transthyretin that has been filed for US approval in transthyretin amyloid cardiomyopathy (ATTR-CM), and now it has a pair of investors who appear to share that bullish sentiment. The Palo Alto, CA-based firm announced a set of transactions on 18 January that ultimately could bring it $1.25bn via a royalty agreement and a pair of financings.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?